Brian Hurley

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Tammie C. Yeh, Vivienne Marsh, Bryan A. Bernat et al. · Clinical Cancer Research · 2007 · 583 citations · Full text

Medicine, Oncology, Pharmacology +14

COVID-19 Adaptations in the Care of Patients with Opioid Use Disorder: a Survey of California Primary Care Clinics

Lauren Caton, Hannah Cheng, Hélène Chokron Garneau et al. · Journal of General Internal Medicine · 2021 · 40 citations · Full text

Nursing, Family Medicine, Behavioral Health +12

Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor

Patrice A. Lee, Eli Wallace, Allison Marlow et al. · Cancer Research · 2010 · 37 citations

Medicine, Oncology, Pharmacology +17

Organizing Publicly Funded Substance Use Disorder Treatment in the United States: Moving Toward a Service System Approach

Howard Padwa, Darren Urada, P. Gauthier et al. · Journal of Substance Abuse Treatment · 2016 · 35 citations

Public Affairs, Health Policy, Health Services Administration +11

Expanding access to medications for opioid use disorder in primary care clinics: an evaluation of common implementation strategies and outcomes

Hannah Cheng, Mark P. McGovern, Hélène Chokron Garneau et al. · Implementation Science Communications · 2022 · 25 citations · Full text

Nursing, Health Services Administration, Implementation Science +13